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Abstract  
When to stop anti-TNF therapy in Crohn's disease (CD)? This is a very important question both for patients and 
physicians. There is no published evidence to clearly and definitely answer this question. However data on 
natural history of CD, long term safety of biologies, outcome after immunosuppressors (IS) cessation and some 
preliminary studies on biologies cessation may help us to discuss this topic. One could argue that there is 
currently no good reason to stop anti-TNF therapy in a patient who is in stable remission and can tolerate this 
drug very well. The decision to stop an anti-TNF treatment is thus currently based on a compromise between the 
benefits/risks and cost of such long term treatment. While it appears now clearly that prolonged anti-TNF 
therapy is associated with favourable outcome with sustained remission, reduced surgeries and hospitalisation as 
well as absence of significant increase in mortality or cancers, the cost-effectiveness which is probably 
favourable for short and mid-term treatment (up to one year), may be less optimal for very long term treatment. 
In this perspective however, prospective studies should be performed to adequately assess long term evolution, 
disease outcome, safety and global cost of strategies based on treatment reduction with IS maintenance alone or 
even full treatment cessation. 




The question of anti-TNF treatment duration in CD is certainly a very important one and is one of the greatest 
preoccupations of patients. When starting a new treatment in CD, one of the first questions the patients may have 
is usually: "when will I be able to stop this treatment"? While the question is very relevant, we actually have 
very little data to give a clear answer, because the controlled data we have with pivotal trials usually give us 
efficacy data for remission and response induction and for remission and response maintenance over a one year 
period [1-3]. 
However we have most often indirect elements to help us and discuss this point of optimal duration of anti-TNF 
treatment in CD: these elements are the natural history of the disease, the available data with immunosuppressive 
drugs, the long term safety of biologies, and a few investigator-initiated studies having started to address this 
question. Beyond that, the cessation of a biological treatment in IBD must be decided on a case-by-case basis 
and adapted strategies must be proposed. The cost of such long term treatment may also become an important 
issue. While we now tend to use anti-TNF earlier in the disease and in a larger proportion of the patients, the 
cost-effectiveness of such strategies over the very long term must be questioned. 
NATURAL HISTORY OF CD 
CD is considered as a chronic relapsing disease, but in a large proportion of patients, it is actually a chronic 
active disease. Population-based and cohort studies have showed that only a small half of the patients have little 
evolutive disease with low prevalence of relapses, hospitalizations, or complications [4-7]. These patients 
probably do not need anti-TNF therapy and if such treatment has been used, an arrest must certainly be discussed 
as soon as the flare has been controlled. The other patients will develop complications including strictures and 
internal or perianal fistulas over the course of the disease [8, 9]. These will lead to hospitalizations and surgeries 
and will considerably interfere with patients every day life and long term projects. For these patients a sustained 
control of the disease process is strongly warranted and an effective treatment can only be stopped if reasonable 
evidence shows absence of activity of this process. There is probably a difference between early disease and 
long-lasting disease, the reversal and control of the disease process being more difficult and unstable in the latter 
situation. Long-lasting disease are indeed characterized by anatomical damages including mucosal and 
submucosal architectural changes, fibrosis, strictures and complex fistulas that will favour clinical relapse and 
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that will render a deep and stable remission more difficult to achieve. Furthermore, immunological status of the 
patients may change over the course of the disease [10]. In parallel, immunisation against luminal material may 
increase, enhancing the potential reactivation of the immune process [11, 12, 13]. As a correlate, a stable 
remission will usually be more difficult to obtain in long-lasting diseases [14] and these diseases will usually be 
more treatment-dependent. This certainly represents an argument for earlier treatment with anti-TNF in CD. 
These patients being treated earlier with anti-TNF and in whom a more complete reversal of the immune process 
and the tissue lesions can be achieved are also probably better candidates for treatment cessation. 
OUTCOME AFTER IMMUNOSUPPRESSOR DISCONTINUATION 
Although immunosuppressive drugs are globally less effective than anti-TNF in CD, inducing less clinical 
remission and less mucosal healing [15], the outcome after discontinuation of these drugs may help to imagine 
what would happen after anti-TNF cessation. In an observational GETAID study of relapse after azathioprine 
cessation in CD, it was shown that the longer the duration of remission under azatioprine, the lowest the risk of 
relapse was [16]. Particularly, the risk of relapse seemed particularly low after 4 years of sustained remission. 
The same group then embarked a placebo-controlled trial of azathioprine prolonged treatment beyond 42 months 
of sustained remission [17]. This trial showed that the strategy of treatment cessation was not equivalent to 
treatment prolongation. Particularly, 18-months relapse rate were around 20% in the cessation group as 
compared to 10% in the prolongation group. Over a longer follow-up period, the relapse rate in the azathioprine 
cessation group continued to increase up to 60% after 3 years [18]. This study indicates that even in patients in 
stable remission, the cessation of an immunosuppressive drug is associated with an increased risk of relapse. The 
risk of relapse in the cessation group remains however reasonably low over a one year period and one could 
consider drug cessation for a given period of time, on a case-by-case basis after discussion with the patients. No 
such data are available with methotrexate in CD. The big difference between immunosuppressor and anti-TNF 
cessation is that in the former situation, no active drug is left to treat the patient, while in the case of anti-TNF 
discontinuation an immunosuppressive drug can be given as maintenance therapy. 
LONG TERM SAFETY OF ANTI-TNF 
While short and mid term safety and tolerance of anti-TNF is usually very good, the fear of long term 
complication is generally the reason why both patients and physicians would like to stop the drug when the 
disease has been completely stabilized. This fear is based on the mechanism of action of these drugs. They block 
the tumor necrosis factor alpha which is a pivotal cytokine in some anti-microbial and anti-tumoral physiological 
processes. Indeed, the best documented side-effects are the increased risk of tuberculosis [19] and of other 
infections, mainly with intra-cellular pathogens (mycobacteria, lysteria, histoplasmosis...), as well as a probable 
slight increase in the risk of lymphoma [20]. The active and systematic search for latent tuberculosis has already 
significantly decreased the incidence of active tuberculosis under anti-TNF treatment. Furthermore, a recent 
meeting of the European Crohn and Colitis Organisation on infections and biologies has proposed a series of 
guidelines, including vaccination against herpes zoster, hepatitis B, influenza and streptococcus pneumoniae as 
well as avoiding some aliments potentially containing germs as lysteria (i.e. unpasteurized milk or insufficiently 
cooked meat) [21]. These guidelines should also in a near future help and diminish fatal complications linked to 
biologies. Another measure that gains more and more support is the avoidance of long term combined treatment 
with immunosuppressors. While over the short term and in immu-nosuppressor-naïve patients a combination 
therapy revealed superior to either immunosuppressor or anti-TNF monotherapies [15], there is currently very 
little evidence for a cumulative benefit of these drugs over a longer term or in immunosuppressor failures [1, 2, 
22]. On the other hand, combined therapies were associated in a retrospective study with a very significant 
increase in the risk of opportunistic infections with a relative risk of 12 when two treatments were combined 
[23]. It is of note however that in this study many opportunistic infections recorded were very benign and that it 
is mmainly the combination of immunosuppressor or anti-TNF with steroids which was associated with such 
infection while there were too few patients under immunosuppressor and anti-TNF combination to draw any 
conclusion on this type of co-treatment. Nevertheless, in the reported pediatric series of nearly universally fatal 
hepato-splenic T cell lymphoma in infliximab treated patients, all the patients affected had been treated with 
combined therapy with thiopurines [24]. All together, these measures should lower the risk profile associated 
with biologies and allow the physician to prescribe them for enough time to achieve stable and durable remission 
of the disease. 
AVAILABLE STUDIES ON ANTI-TNF TREATMENT CESSATION IN IBD 
Early data with infliximab in CD were only short term induction data [25]. Only one single infusion was used at 
that time and it is striking to note that some patients had a very prolonged clinical response or even remission 
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after such isolated infusion [26]. These data already suggested that prolonged treatment was probably not 
necessary in all the treated patients. Since then however, it has become clear that such one-shot treatment was 
not a good option for the majority of patients because the median time to relapse was 10 weeks and because re-
use of infliximab more than 4 months after a single infusion was associated with high risk of allergic reaction. 
More recently the "bridge" study of the GETAID explored the idea of a 3-dose infliximab induction given in 
parallel with immunosuppressor that would then maintain the remission [27]. The results of this study were 
rather disappointing. While the short term effect of infliximab was very strong, the maintenance effect with 
immunosuppressor was globally rather weak. After one year, the overall sustained remission rate in these 
patients was low and actually close to the one of patients receiving a placebo induction. Only in the patients who 
were immunosuppressor-nai've at the time of infliximab induction, the benefit was more consistent with a 
reasonable 40% remission rate after one year. This study clearly shows that in patients who have failed under 
immunosuppressors, a longer period of anti-TNF treatment is necessary to obtain a durable remission and allow 
treatment cessation. Long term results of the large Leuven cohort of patients treated with infliximab indicate that 
in real life, a significant proportion of patients (around 20%) are in sustained remission despite infliximab 
cessation [28]. This possibility has been prospectively explored in a recent GETAID study, only published in 
abstract form [29]. In this prospective cohort study, 115 patients with a stable remission on combined 
immunosuppressor-infliximab therapy for more than one year had their infliximab stopped, while pursuing 
immunosuppressive treatment. After one year more than half of the patients were still in sustained remission. 
Factors associated with a low risk of relapse included low CDAI, low highly sensitive CRP, low fecal 
calprotectin, high haemoglobin levels and non smoking. These features indicate that the patients with a low risk 
of relapse are the ones who are in very deep not only clinical, but also endoscopic and biological remission. 
Another important question to address when contemplating anti-TNF discontinuation, is the possibility to restart 
this treatment in case of relapse. Here also the data of the GETAID study may be reassuring, at least over the 
short term, since almost all the relapsers who were retreated were in remission again 4 weeks after first 
retreatment. 
COST-EFFECTIVENESS 
Cost studies in CD have essentially included direct medical costs. First studies were based on models generated 
with data form the literature [30]. These studies indicated that hospitalisations and surgeries represented the 
majority of the direct medical costs (up to 80%) linked to CD. They were further confirmed by several 
retrospective and prospective cohort analyses [31, 32], suggesting that a therapeutic strategy that would decrease 
the number of hospitalisations and/or surgeries in CD might have an important impact on direct medical costs. 
Prospective studies with both infliximab and adalimumab given for induction of remission and then maintenance 
treatment have showed a significant decrease in both hospitalisations and surgeries with these drugs [33, 34]. 
Globally, this may suggest a potential cost-effectiveness of anti-TNF at least over one year of treatment, 
although no proper cost-effectiveness analysis has been fully published so far. However, beyond one year of 
treatment, the cost-effectiveness of continuous scheduled anti-TNF treatment would require a major superiority 
of this strategy as compared to maintenance with immunosuppressive treatment and/or on demand anti-TNF. In 
view of the preliminary results of the GETAID infliximab discontinuation study mentioned here above [29], this 
result may be difficult to reach, at least in patients in long lasting stable remission. 
PRACTICAL CONSIDERATIONS FOR STOPPING ANTI-TNF TREATMENT IN CD 
Usually, a biological treatment is started in patients who do no longer respond to conventional therapies. In 
patients responding to the treatment, it is certainly not wise to contemplate a treatment cessation as long as a 
complete clinical remission has not been achieved. In patients who have been in clinical remission for a 
sufficient period of time, it is probably useful to assess biological as well as endoscopic signs of disease activity. 
In several models and clinical situations, C-reactive protein (CRP) serum concentration has been associated with 
the risk of relapse [35]. More sophisticated serum or stool markers have also been proposed, but their added 
value as compared to CRP has not been clearly demonstrated [36-38]. A stable value of CRP within normal 
range should therefore also be obtained before anti-TNF cessation. The recent data from the GETAID study may 
even indicate that hsCRP should be preferred to classical CRP in assessing such patients, since mild variations 
within the normal range of classical CRP may have clinical significance to disclose deeper remission [29]. 
Correlation between clinical indexes of activity or biological markers of inflammation and mucosal healing is 
not very strong [39]. Mucosal healing under anti-TNF treatment has been associated with a decrease in relapse 
rate, hospitalisation and surgeries [31]. A third condition for biologies cessation is thus to control for a mucosal 
healing in patients with ileo-colonic disease accessible to endoscopic exploration. For patients with proximal 
small bowel disease, there is not universally accepted exploration to assess the control of inflammation at the 
tissue level. However, entero-MRI could be a good candidate [40]. An absence of mucosal lesion (not always 
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easy to detect), and of contrast enhancement of the bowel wall or the mesenterium could be interpreted as tissue 
healing. Globally, fecal calprotectin is now considered as a relatively good surrogate marker for mucosal healing 
[38, 41-42]. However, this correlation has been shown to be stronger for ulcerative colitis than for CD. 
Furthermore fecal calprotectin appears to be essentially correlated with colonic mucosal lesions while the 
correlation with small bowel lesion is much weaker. Nevertheless, in the above-mentioned GETAID study [29], 
fecal calprotectin was in univariate analysis the factor most strongly associated with the time-to-relapse. It is 
however too early to say that, at least for colonic disease, it could replace endoscopy for patient's assessment. 
CONCLUSIONS 
Globally, the decision to stop or carry on with anti-TNF treatment in CD is based on an estimated benefit-risk 
ratio and on the cost-effectiveness of long term treatment. The patient must certainly be fully and clearly 
informed on both advantages and risks linked to any therapeutic strategy that is proposed. In patients with 
unstable chronic active disease, stopping an effective treatment will put the patients at risk of worsening and 
complications development and should probably not be attempted. However in patients stabilized for a 
reasonably long period of time, a careful assessment of the clinical, biological and endoscopic situation may help 
to take a thoughtful decision in collaboration with the patient himself. From the payer's point of view, this may 
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